Gabrièle Laborde-Balen, Bernard Taverne, Cheikh Tidiane Ndour, Charles Kouanfack, Martine Peeters, Ibra Ndoye, Eric Delaporte
In The Lancet Infectious Diseases, Ravindra Gupta and colleagues1 present alarming results on the development of pre-treatment viral resistance to the most commonly used drugs to treat HIV infection in resource-limited countries.
Tingathe Outreach Program, Baylor College of Medicine Children's Foundation-Malawi
Tuberculosis (TB) is the 9th leading cause of death worldwide.1 While TB mortality and incidence are decreasing, there are still significant gaps in detection and treatment.2 One in four new TB cases occurred in Africa in 2016, and co-infection with HIV is a notab
We have come a long way in our response to the HIV epidemic since its beginning. Many critical steps have been made. In the last seven years, new HIV infection rates have dropped almost 30 percent worldwide.
Before joining the LINKAGES project, I spent most of my career developing, managing, and evaluating gender-based violence (GBV) prevention and response programs for women and girls in emergency, post-conflict, and development settings, as well as in the U.S.
Solange Baptiste, Executive Director at the International Treatment Preparedness Coalition (ITPC)
There is a clear appreciation for the pivotal role that communities have played in the HIV response over the last 32 years, but it’s no surprise that critical gaps remain – particularly with respect to the ways communities are effectively and meaningfully engaged in their care and treatment.
Mark Mascolini is a medical journalist who writes about HIV news, research and global policies for the International AIDS Society and many publications. Emily Bass is the Director of Strategy & Content at AVAC.